Premium
Clinical pharmacologic investigations with carvedilol, a new beta‐blocker with direct vasodilator activity
Author(s) -
Möllendorff Erika v,
Abshagen Ulrich,
Akpan Waltraud,
Neugebauer Günter,
Schröter Eva
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.118
Subject(s) - carvedilol , vasodilation , medicine , plethysmograph , clinical pharmacology , forearm , cardiology , beta blocker , vascular resistance , anesthesia , pharmacology , heart failure , hemodynamics , surgery
Carvedilol (BM 14.190) has been shown to have β‐adrenergic blocking and vasodilating activity. By means of digital plethysmography, the threshold for vasodilation was ascertained at a dose of 2.6 mg iv infused over 1 hour. The oral threshold dose was established at about 15 mg, with a linear increase in response (r = 0.78) up to 76.5 mg. This dose increased blood flow to the forearm by reduction of arterial resistance. Although venous capacity was not changed, postural symptoms in three subjects could also be indicative of venous involvement. Carvedilol, 50 mg, reduced exercise heart rate for about 10 hours. Clinical Pharmacology and Therapeutics (1986) 39, 677–682; doi: 10.1038/clpt.1986.118